UBS Group’s Aspire Biopharma ASBP Stock Holding History

UBS Group’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5	Sell	1 -6,382	-100%	-$65.1K	﹤0.01%	10354
2026 Q1	$197K	Buy	6,383 +4,287	+205%	+$228K	﹤0.01%	6644
2025 Q4	$332K	Buy	2,096 +2,090	+34,833%	+$523K	﹤0.01%	6301
2025 Q3	$1.58K	Buy	+6	New	+$3K	﹤0.01%	9315
2025 Q2	–	Sell	-25	Closed	-$17.5K	–	11117
2025 Q1	$17.5K	Buy	+25	New	+$173K	﹤0.01%	8319
2024 Q4	–	Hold	0	–	–	–	9441
2024 Q3	–	Sell	-1	Closed	-$8.75K	–	10232
2024 Q2	$8.75K	Buy	+1	New	+$13.6K	﹤0.01%	7781
2024 Q1	–	Hold	0	–	–	–	8481
2023 Q4	–	Hold	0	–	-$650	–	10032
2023 Q3	–	Hold	0	–	–	–	8352
2022 Q4	–	Sell	-41	Closed	-$497K	–	11245
2022 Q3	$497K	Hold	41	–	–	﹤0.01%	4349
2022 Q2	$487K	Buy	+41	New	+$491K	﹤0.01%	4273

Other funds holding ASBP

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

VWM

Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return

Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group's ASBP Position: Q2 2026 in Review

UBS Group reduced its Aspire Biopharma (ASBP) stake by 100% in Q2 2026, selling an estimated $65.1K and leaving 1 share worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #10354.

UBS Group first reported a position in ASBP in Q2 2022 and has held it in 8 quarters since. The position peaked at $497K in Q3 2022. 13 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

UBS Group held 1 share of Aspire Biopharma worth $5 as of Q2 2026.
UBS Group sold 6,382 Aspire Biopharma shares in Q2 2026, an estimated $65.1K.
Aspire Biopharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10354 holding.
UBS Group first reported a position in Aspire Biopharma in Q2 2022 and has held it in 8 quarters since.
UBS Group's Aspire Biopharma position peaked at $497K in Q3 2022.
13 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.